Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Bristol-Myers Squibb (BMY) Stock Price & Analysis
10,069 Followers
BMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$44.34 - $66.25
Previous Close$44.85
Volume21.28M
Average Volume (3M)16.09M
Market Cap
$99.29B
Enterprise Value$136.98B
Total Cash (Recent Filing)$9.67B
Total Debt (Recent Filing)$55.68B
Price to Earnings (P/E)-14.5
Beta0.32
Next Earnings
Jul 26, 2024EPS Estimate
$1.69Last Dividend Ex-Date
Apr 04, 2024Dividend Yield5.17%
Share Statistics
EPS (TTM)-3.10
Shares Outstanding2,027,100,096
10 Day Avg. Volume15,630,489
30 Day Avg. Volume16,092,859
Standard Deviation0.06
R-Squared0.13
Alpha0.00194
Financial Highlights & Ratios
Price to Book (P/B)-4.79
Price to Sales (P/S)7.66
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit3.99
Enterprise Value/Ebitda33.12
Forecast
1Y Price Target
$53.36Price Target Upside18.97% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bristol-Myers Squibb News
PremiumCompany Announcements
Bristol-Myers Squibb Q1 Earnings Call Strategy Insights
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company announced a $1.5B cost savings initiative which will be reinvested to improve efficiency.
Financial PerformanceAnalyst's market perform rating suggests that shares are fairly valued with stable cash flows from I/O and hematology businesses.
Product PerformanceReblozyl sales may exceed expectations with strong prescription growth, indicating robust demand.
Bears Say
Financial PerformanceTougher quarter for Bristol with low-quality earnings driven by legacy business, coupled with a reduced target price due to updated growth asset expectations.
Product PerformanceKey growth products like Camzyos, Sotyktu, and Abecma underperformed, indicating challenges in Bristol's growth portfolio.
Strategic ConcernsRecent mergers and acquisitions are considered dilutive in the near term, raising concerns about the short-term financial impact on the company.
---
Ownership Overview
0.30% Insiders
24.11% Mutual Funds
24.21% Other Institutional Investors
51.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $44.34 and its highest was $66.25 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Jul 26, 2024 which is in 89 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Apr 25, 2024. The company reported -$4.4 earnings per share for the quarter, beating the consensus estimate of -$4.412 by $0.012.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 5.17%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.69.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,100,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of -$4.4 in its last earnings report, beating expectations of -$4.412. Following the earnings report the stock price went down -8.514%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.36 (18.97% Upside)
$53.36 (18.97% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.23%
12-Months-Change
Fundamentals
Return on Equity
-25.45%
Trailing 12-Months
Asset Growth
5.04%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q1 2024
0:00 / 0:00
---
BMY Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BMY Stock 12 Months Forecast
Average Price Target
$53.36
▲(18.97% Upside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+14.39%
reiterated a sell rating 19 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +14.39% per trade.
---